PMID- 37257227
OWN - NLM
STAT- MEDLINE
DCOM- 20231113
LR  - 20231113
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 164
DP  - 2023 Aug
TI  - Advances in dendritic cell vaccination therapy of cancer.
PG  - 114954
LID - S0753-3322(23)00744-8 [pii]
LID - 10.1016/j.biopha.2023.114954 [doi]
AB  - Traditionally, vaccines have helped eradication of several infectious diseases 
      and also saved millions of lives in the human history. Those prophylactic 
      vaccines have acted through inducing immune responses against a live attenuated, 
      killed organism or antigenic subunits to protect the recipient against a real 
      infection caused by the pathogenic microorganism. Nevertheless, development of 
      anticancer vaccines as valuable targets in human health has faced challenges and 
      requires further optimizations. Dendritic cells (DCs) are the most potent antigen 
      presenting cells (APCs) that play essential roles in tumor immunotherapies 
      through induction of CD8(+) T cell immunity. Accordingly, various strategies have 
      been tested to employ DCs as therapeutic vaccines for exploiting their activity 
      against tumor cells. Application of whole tumor cells or purified/recombinant 
      antigen peptides are the most common approaches for pulsing DCs, which then are 
      injected back into the patients. Although some hopeful results are reported for a 
      number of DC vaccines tested in animal and clinical trials of cancer patients, 
      such approaches are still inefficient and require optimization. Failure of DC 
      vaccination is postulated due to immunosuppressive tumor microenvironment (TME), 
      overexpression of checkpoint proteins, suboptimal avidity of tumor-associated 
      antigen (TAA)-specific T lymphocytes, and lack of appropriate adjuvants. In this 
      review, we have an overview of the current experiments and trials evaluated the 
      anticancer efficacy of DC vaccination as well as focusing on strategies to 
      improve their potential including combination therapy with immune checkpoint 
      inhibitors (ICIs).
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Najafi, Sajad
AU  - Najafi S
AD  - Department of Medical Biotechnology, School of Advanced Technologies in Medicine, 
      Shahid Beheshti University of Medical Sciences, Tehran, Iran; Cellular and 
      Molecular Biology Research Center, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Mortezaee, Keywan
AU  - Mortezaee K
AD  - Department of Anatomy, School of Medicine, Kurdistan University of Medical 
      Sciences, Sanandaj, Iran. Electronic address: keywan987@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230529
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Antigens, Neoplasm
MH  - *Cancer Vaccines/therapeutic use
MH  - CD8-Positive T-Lymphocytes
MH  - *Dendritic Cells
MH  - *Neoplasms/metabolism
MH  - Tumor Microenvironment
MH  - Vaccination
OTO - NOTNLM
OT  - Cancer, immune checkpoint inhibitor (ICI), programmed death-1 (PD-1), tumor 
      microenvironment (TME)
OT  - Dendritic cell (DC)
OT  - Vaccination
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/06/01 01:08
MHDA- 2023/06/22 06:42
CRDT- 2023/05/31 18:01
PHST- 2023/04/10 00:00 [received]
PHST- 2023/05/16 00:00 [revised]
PHST- 2023/05/27 00:00 [accepted]
PHST- 2023/06/22 06:42 [medline]
PHST- 2023/06/01 01:08 [pubmed]
PHST- 2023/05/31 18:01 [entrez]
AID - S0753-3322(23)00744-8 [pii]
AID - 10.1016/j.biopha.2023.114954 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2023 Aug;164:114954. doi: 10.1016/j.biopha.2023.114954. Epub 
      2023 May 29.